Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 4, 2025 • 2:00 AM ET

Date/Time Source News Release
11/20/2024 07:02 AM EST GlobeNewswire Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
09/26/2024 06:44 PM EDT GlobeNewswire Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
09/26/2024 07:02 AM EDT GlobeNewswire Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
09/09/2024 08:01 AM EDT GlobeNewswire Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
09/03/2024 08:02 AM EDT GlobeNewswire Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
08/28/2024 09:11 AM EDT GlobeNewswire Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
06/13/2024 06:59 AM EDT GlobeNewswire Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
05/28/2024 06:59 AM EDT GlobeNewswire Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
04/29/2024 07:59 AM EDT GlobeNewswire Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
04/24/2024 07:59 AM EDT GlobeNewswire Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Page

Additional News

As of January 4, 2025 • 2:00 AM ET

Date/Time Source News Release
11/27/2024 04:31 AM EST US Earnings Reports Expected earnings - Pasithea Therapeutics Corp.
10/07/2024 06:40 PM EDT Stock Traders Daily (KTTA) Investment Analysis
10/07/2024 04:52 PM EDT SeekingAlpha Pasithea Therapeutics files to sell 3.74M shares of common stock for holders
09/27/2024 03:50 AM EDT SeekingAlpha Pasithea Therapeutics drops 19% on $5M private placement
09/26/2024 04:30 PM EDT QM US Market Movers News US Companies Moving the Markets, Evening edition
Thu, Sep 26, 2024 as of 4:00 pm ET
09/26/2024 12:59 PM EDT InvestorBrandNetwork Pasithea Therapeutics Corp. (NASDAQ: KTTA) Near the Top of Equities by Percentage Gain on 9/26
09/26/2024 10:00 AM EDT QM US Market Movers News US Companies Moving the Markets, Morning edition
Thu, Sep 26, 2024 as of 10.00 am ET
08/07/2024 05:46 PM EDT Stock Traders Daily (KTTA) Pivots Trading Plans and Risk Controls
05/15/2024 05:37 AM EDT US Earnings Reports Expected earnings - Pasithea Therapeutics Corp.
05/07/2024 05:12 PM EDT Stock Traders Daily When the Price of (KTTA) Talks, People Listen
Page